Ritter Pharmaceuticals, Inc. (“Ritterâ€) is committed to the discovery, development and commercialization of innovative therapeutic treatments for gastrointestinal diseases. Ritter’s first target compound, RPâ€G28, has the potential to become the first FDAâ€approved drug for the treatment of lactose intolerance, a condition that effects 80 million Americans and 4.3 billion worldwide. RPâ€G28 works by stimulating the colonic growth and colonizing lactoseâ€fermenting bacteria in the colon, which reduces lactoseâ€derived gas production, and thereby mitigates the symptoms of lactose intolerance. The drug is a 35 day treatment and only periodic maintenance treatments are needed thereafter.
